Mabpharm Limited
HHKEX:21810.46
HKD
+0.02
(+4.55%)
Mabpharm Limited
HKEX:2181
(Hong Kong Exchange)
Recent
price
0.46
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Semi-annual Revenue
CNY
•
in mil. unless spec.Semi-annual Earnings Per Share
CNY
•
in mil. unless spec.Semi-annual Dividends Per Share
CNY
•
in mil. unless spec.- Similar Companies
- Business
- Mabpharm Limited Mabpharm Limited (2181.HK) is a China-based biopharmaceutical company that engages in the research, development, production, and commercialization of monoclonal antibody drugs and biosimilars primarily for the treatment of cancer and autoimmune diseases; its core approved products include CMAB009 Enlituo (cetuximab beta injection) for first-line treatment of RAS/BRAF wild-type metastatic colorectal cancer in combination with FOLFIRI, CMAB007 Aomaishu (omalizumab alpha for injection) for moderate-to-severe persistent allergic asthma and chronic idiopathic urticaria, and CMAB008 Leiting (infliximab for injection) for rheumatoid arthritis, Crohn's disease, and ulcerative colitis; the company's pipeline further encompasses Phase III candidates such as CMAB819 for metastatic non-small cell lung cancer, hepatocellular carcinoma, and head and neck squamous cell carcinomas, alongside preclinical-stage assets including CMAB017 for advanced solid tumors, CMAB018 (mepolizumab biosimilar) for asthma, and CMAB023 (tezepelumab biosimilar) for asthma and related conditions. Mabpharm Limited operates a large-scale GMP antibody production base through its wholly-owned subsidiary Taizhou Mabtech Pharmaceutical Co., Ltd., equipped with multiple 1,500-liter bioreactors, filling lines producing millions of vials and prefilled syringes annually, and capabilities in contract development and manufacturing organization (CDMO) services; it primarily serves the domestic Chinese market with expansion into intellectual property transfers and international branding efforts. Founded in 2005 and listed on the Hong Kong Stock Exchange in 2019 with headquarters in Taizhou, Zhejiang Province, China, the company marked a key milestone in June 2024 with regulatory approval of CMAB009 by the National Medical Products Administration, enhancing its oncology portfolio amid ongoing advancements in its nine monoclonal antibody and one probody drug pipeline.